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Abstract  
Objectives: To test whether or not one out two biologic mediators (recombinant human bone 
morphogenetic protein-2 (rhBMP-2) and recombinant human platelet-derived growth factor 
(rhPDGF-BB)) is superior to the other and compared to control groups for bone regeneration 
around implants based on histomorphometric outcome measures. 
Materials and methods: Box-type defects (10 × 5 x 5 mm) were prepared on the buccal sides 
of the left and right edentulous ridge in ten mongrel dogs. Implants were placed at each site, the 
defects either received (i) bovine-derived particulated bone mineral (DBBM) mixed with rhBMP-
2 and a collagen membrane (CM) (DBBM/BMP-2), (ii) DBBM mixed with rhPDGF-BB and CM 
(DBBM/PDGF), (iii) DBBM and CM (DBBM), and (iv) empty control (control). Animals were 
euthanized post-surgery at 8 weeks and 16 weeks. Histomorphometric analyses were 
performed.  
Results: The mean percentages of regenerated area within total defect area amounted to 
56.95% for DBBM/BMP-2, 48.86% for DBBM/PDFG, 33.44% for DBBM and 1.59% for control at 
8 weeks, and at 16 weeks 26.79% for DBBM/BMP-2, 23.78% for DBBM/PDFG, 30.21% for 
DBBM and 5.07% for control with no statistically significant differences between the groups 
(p>0.05). The mean amount of regenerated bone was 26.97% for DBBM/BMP-2, 22.02% for 
DBBM/PDFG, 5.03% for DBBM and 1.25% for control at 8 weeks and at 16 weeks, these values 
were lower in the two groups with biological mediators (DBBM/BMP-2=13.35%; 
DBBM/PDGF=6.96%) and only slightly increased in group DBBM (10.68%) and the control 
group (4.95%) compared to 8 weeks. The first bone to implant contact values on the buccal side 
were minimal for DBBM/BMP-2 (0.57mm) and maximal for control (3.72mm) at 8 weeks. 
Conclusions: The use of biologic mediators (rhBMP-2, rhPDGF-BB) can increase the 
amount of bone regeneration at dehiscence-type defects compared to controls at 8 weeks, but 
not at 16 weeks due to enhanced hard tissue remodeling processes.  
. 
 
  
Introduction 
Guided bone regeneration (GBR) procedures are routinely performed in dental practice 
to regenerate missing hard and soft tissue volume prior to or simultaneously with dental implant 
placement (Hämmerle et al. 2002; Bornstein et al. 2008). For that purpose, autogenous bone or 
bone substitute materials in combination with non-resorbable barrier membranes are used. 
These membranes offer advantages in terms of the stability of the augmented site and render 
high clinical success rates (Friedmann et al. 2001; von Arx et al. 2001; Buser et al. 2002). 
Though, clinical disadvantages include: an additional surgical procedure to remove the 
membrane and increased rates of membrane exposure (Becker et al. 1994; Simion et al. 1994; 
Strietzel 2001). In order to overcome these shortcomings, resorbable membranes were 
introduced. Among these, collagen membranes are well documented and have shown to render 
high success rates (Pitaru et al. 1987; Zitzmann et al. 1997; Zitzmann et al. 2001; Hockers et al. 
1999; Friedmann et al. 2001). However, these relatively soft membranes do not maintain space 
per se and a compression of the regenerated site can potentially result in a displacement of the 
augmentation material (Strietzel et al. 2006). 
More recently, bone regeneration was performed applying the principles of tissue 
engineering (Gothard et al. 2014), focused on the investigation of bioactive molecules to induce 
local bone formation. Based on a number of systematic reviews, the most promising factors for 
localized ridge augmentation include recombinant human bone morphogenetic protein-2 
(rhBMP-2) and recombinant platelet-derived growth factor (rhPDGF-BB) (Jung, Thoma & 
Hämmerle 2008; Fisher et al. 2013; Khojasteh et al. 2013). 
RhBMP-2 promotes better results on ridge regeneration following socket grafting (Lee 
et al. 2015) and bone regeneration and osseointegration around dental implants (Jung et al. 
2003, 2009; Jung et al. 2015; Kim et al. 2015). RhPDGF-BB has been employed in the field of 
periodontology in combination with various carrier materials for the treatment of infrabony 
defects (Nevins et al. 2005, 2013; Jayakumar et al. 2011; Thakare & Deo 2012; Khoshkam et al. 
2015). In implant dentistry, rhPDGF-BB has been used to enhance bone formation in localized 
bone defects and for vertical ridge augmentation (Simion et al. 2006; Simion et al. 2007; Nevins 
et al. 2009, 2012; McAllister et al. 2010; Thoma et al. 2012; Xu et al. 2016). 
Whereas both, rhBMP-2 and rhPDGF-BB have been successfully used in various 
animal models and clinical applications (Boyan et al. 2000; Cochran et al. 2000; Jung et al. 
2003; Simion et al. 2006; Thoma et al. 2010; Darby & Morris 2013), no data can be retrieved 
from the literature comparing the two biological mediators for guided bone regeneration around 
dental implants in the same experimental model.  
Therefore, the aims of the study were to test whether or not one out of two biological 
mediators (rhPDGF-BB or rhBMP-2) is superior to the other and compared to control groups for 
bone regeneration around implants based on histological and histomorphometric outcome 
measures. 
Materials and Methods 
The study was designed as a randomized experimental study employing 10 healthy 
adult beagle dogs (weight=15kg) . The animals were kept in a purpose-designed room for 
experimental animals and were fed a standard laboratory diet. The study was approved by the 
institutional animal care and use committee of Yonsei medical center, Seoul, Korea (permission 
no.: 2013-0317). 
All the materials used in the present study are commercially available. Preparation of 
rhBMP-2 (Cowellmedi, Busan, Republic of Korea) was similar to a previous report (Jung et al. 
2015). RhPDGF-BB (GEM 21S®, Osteohealth, BioMimetic Therapeutics Inc., USA) was 
purchased from the manufacturer.  
Surgical Procedure 
The surgical procedure has been described in the previous report (Jung et al. 2015). In brief, all 
surgical procedures were performed under general anesthesia. Subsequently, local infiltration 
anesthesia was additionally injected at the surgical site.  
Surgery 1 
After mucoperiostal flaps were reflected bilaterally in the mandible, the third and fourth 
premolar as well as the first molar (P3, P4, M1) were carefully removed. Primary wound closure 
was obtained using monofilament sutures (Monosyn® 4.0 Glyconate Monofilament, B. Braun 
Tuttlingen, Germany). Additional medications were administrated after the surgeries, including 
an antibiotic prophylaxis (Moxicle, Daewoong Pharm., Gyeonggido, Korea), an anti-
inflammatory and an analgesic drug (Ketorolac, Hana Pharm., Gyeonggido, Korea; Meloxicam, 
Boehringer Ingelheim, Bogota D.C., Colombia) for 7 days. 
Surgery 2 
After three months of healing, defect preparation, implant placement and GBR 
procedures were performed in all dogs. Following a mid-crestal incision, mucoperiostal flaps 
were reflected to expose the buccal and lingual alveolar plate. A vertical releasing incision was 
placed distal to the canine. All granulation tissue was carefully removed and the edentulous 
ridge was flattened to obtain a width of at least 7 mm. Two implant sites were prepared 
bilaterally under abundant irrigation with sterile saline, at a distance of 14 mm apart and at the 
same distance from the buccal cortical bone plate. Following implant site preparation, two 
standardized box-shaped defects (mesio-distal width: 10 mm, depth: 5 mm, height: 5 mm) were 
prepared bilaterally at the buccal aspect of the mandibular alveolar ridge (Fig. 1a & b). The 
defect sites were standardized using a periodontal probe and rinsed with sterile saline to 
completely remove any residual debris. Thereafter, screw-type titanium implants (length 8 mm, 
diameter 4.0 mm, Astra Tech, OsseoSpeed™ TX 4.0 S, DENTSPLY Implants, Mölndal, 
Sweden) were inserted with good primary stability in a way that the implant shoulder coincided 
with the bone crest at the lingual aspect. Titanium closure screws were applied.  
The buccal dehiscence-type defects were allocated based on a computer software 
generated randomization list and the use of sealed envelopes. The treatment modalities were 
applied: 
i. DBBM/BMP-2 group: Deproteinized bovine bone mineral (DBBM; BioOss® granules, 
particle size 0.25-1 mm, Geistlich, Wolhusen, Switzerland) mixed with rhBMP-2 (Cowellmedi, 
Busan, Republi of Korea) + collagen membrane (CM; BioGide®, Geistlich, Wolhusen, 
Switzerland).  
ii. DBBM/PDGF group: DBBM mixed with rhPDGF-BB (GEM 21S®, Osteohealth, 
BioMimetic Therapeutics Inc., USA) + CM. 
iii. DBBM group: DBBM + CM. 
iv. Control group: no treatment . 
At the sites allocated for the use of bone substitutes, the defects were filled with a 
standardized amount of biomaterial (DBBM). For the DBBM/BMP-2 and DBBM/PDGF groups, 
0.1 ml of rhBMP-2 (Cowellmedi, Busan, Korea) or rhPDGF-BB (GEM 21S®, Osteohealth, 
BioMimetic Therapeutics Inc., USA) at a concentration of 0.3 mg/ml was loaded onto 0.07 g of 
DBBM granules (BioOss®, Geistlich Biomaterials, Wolhusen, Switzerland), respectively. Three 
minutes of binding time was provided for both groups. For the DBBM group, 0.1 ml of saline was 
mixed with DBBM. The DBBM biomaterial was covered with a CM in order extending 2 mm 
beyond the defect margins (Fig. 1c, d & e). Before applying the membrane, the horizontal defect 
extensions were measured from the buccal implant surface to the most buccal aspect of the 
graft material. Bleeding was allowed to form a blood clot in empty sites, where no further 
treatment was applied. Resorbable polylactide pins (Inion CPS, Inion Ltd., Tampere, Finland) 
were inserted apically at all the sites in order to stabilize the membranes. 
Following periosteal-releasing incisions, the mucoperiostal flaps were advanced 
coronally and primary wound closure was achieved by placing horizontal mattress sutures and 
interrupted sutures (4-0 Monosyn Glyconate Monofilament; B. Braun, Tuttlingen, Germany). The 
sutures were removed 14 days after surgery 2. 
After a healing period of 2 months (n=5) and 4 months (n=5), the animals were 
terminated by an overdose of potassium chloride 3g (Daihan Potassium chloride-40, Daihan 
pharm., Ansan, Korea). The jaws were dissected and blocks containing the experimental 
specimens with intact soft tissues were obtained.  
Histological preparation 
The specimens were fixed in 10% formalin for 2 weeks. An EXAKT cutting system 
(EXAKT® Apparatebau, Norderstedt, Germany) was used to cut the specimens at the center of 
the implant in a mesio-distal direction. The specimens were dehydrated in an ascending series 
of alcohol and subsequently embedded in methacrylate-based resin, polymerized and then fixed 
to the vacuum head of the EXAKT macro cutter. The thickness of sections was prepared with 
approximately 100 µm and then ground and polished on the EXAKT micro grinder to a thickness 
of 15 µm. Paragon was used to stain the microscope slides. 
Histomorphometrical analysis  
Computer-assisted histomorphometric measurements were obtained using an 
automated image analysis system (LAS V4.3, Leica Microsystems, Wetzlar, Germany), coupled 
with a photo camera (Leica DFC450, Leica Microsystems, Wetzlar, Germany) mounted on a 
light microscope (Leica DM6000 B, Leica Microsystems, Wetzlar, Germany).  
In the central sections, the region of interest (ROI) was determined (Fig. 2a) and the 
following parameters were calculated (Fig. 2b & c): 
-Total defect area (mm2; TDA); 
-Regenerated area (mm2; RA); 
-Percentage of regenerated area within total defect area (%; RA/TDA); 
-The percentage of regenerated bone, bone substitute material, mineralized tissue 
(bone + bone substitute material), soft tissue and background within TDA (%); 
-The first bone to implant contact (mm; fBIC), measured from the implant shoulder to 
the first bone to implant contact on the buccal (fBICb) and lingual (fBICl) side. 
Statistical Analysis 
The metric variables were described with mean, median, standard deviation and 
quartiles. The comparisons of the four group means for the metric variables were performed 
using mixed linear models since the data within a dog were dependent (clustered). The dog was 
set as random effect in these models. The assumptions of these models were validated also in 
view of the small sample sizes. 
Results  
The animals did not present signs of postoperative infections or weight reduction. There 
were no local complications in surgical areas during the entire study period.  
Descriptive histology  
All implants were well-osseointegrated. In the majority of the sites, the most coronal 
bone-to implant contact was close to the implant shoulder on the lingual side. On the buccal 
side, in a majority of sites, the fBIC was located more apical compared to the lingual side. In all 
sites, the soft tissues covered the implants, even in cases with implants threads not being 
covered with mineralized tissue. Within the augmented area, angiogenesis was observed in all 
groups at 8 and 16 weeks. In empty sites, this revascularization was predomiantly close to the 
implant surface and the apical border of the defect, whereas in all other groups (all with DBBM), 
newly formed blood vessels surrounded the DBBM particles. A relatively small number of 
osteoclasts was located at bone and bone substitute surfaces at 8 weeks. This number 
increased over the next 8 weeks.  
In BMP-2 sites, at 8 weeks, the contour was mostly re-established (Fig. 3a). DBBM 
particles were completely surrounded by woven and lamellar bone. The mucosa did not show a 
collapse of the contour. At 16 weeks, the contour changed and presented a loss (Fig. 4a). 
Moreover, most of the DBBM particles were not present anymore. Lamellar bone formation was 
limited, mostly close to the implant surface. 
At 8 weeks, in PDGF sites, the contour was mostly re-established with the augmented 
area being filled with DBBM particles and woven bone (Fig. 3b). In contrast to DBBM sites, bone 
formation was not limited to the implant surface, but was also evident surrounding the DBBM 
particles. At 16 weeks, part of the contour was lost in most cases, the amount of DBBM particles 
appeared to be less. Moreover, only limited woven and some lamellar bone was observed (Fig. 
4b).  
In DBBM sites, the ridge contour was re-established in most cases, without obvious 
differences between the time-points (Fig. 3c & 4c). Woven bone formation was evident along 
the implant surface, increasing from 8 to 16 weeks. At 8 weeks, the bone-to-bone substitute 
contact was very limited, whereas at 16 weeks, new bone formation (woven and lamellar bone) 
was evident around the DBBM particles.  
In empty sites at both time-points (8 and 16 weeks), the ridge contour was not re-
established demonstrating exposed implant threads on roughly 50% of the implant surface (Fig. 
3d & 4d). Moreover, in a majority of the sites, the vertical dimension of the bone defect was 
even larger compared to the originally established defect dimension. Bone formation at the 
implant surface was not evident. The soft tissues, however, covered all implants, but the 
mucosa appeared to be collapsed. 
Histomorphometrical analysis  
All data are presented in table 1 and table 2. The mean RA/TDA values amounted to 
56.95%±15.84% for DBBM/BMP-2, 48.86%±19.81% for DBBM/PDFG, 33.44%±14.09% for 
DBBM and 1.59%±2.84% for control at 8 weeks. The control group demonstrated statistically 
significantly less RA/TDA at 8 weeks compared to all other groups (p<0.0001 vs. DBBM/BMP-2, 
p=0.0014 vs.  DBBM/PDGF and p=0.0017 vs. DBBM group). At 16 weeks, mean RA/TDA 
values were 26.79%±19.83% for DBBM/BMP-2, 23.78%±22.84% for DBBM/PDFG, 
30.21%±29.14% for DBBM and 5.07%±8.91% for control. At 16 weeks, no statistically 
significant mean differences were found between the groups (p>0.05). 
The mean amount of regenerated bone was 26.97%±12.17% for DBBM/BMP-2, 
22.02%±19.66% for DBBM/PDFG, 5.03%±4.30% for DBBM and 1.25%±2.60% for control at 8 
weeks. The control and DBBM groups demonstrated statistically significant differences in terms 
of newly formed bone compared to DBBM/BMP-2 (p=0.0096 and p=0.0025, respectively). At 16 
weeks, these values were lower in the two groups with biological mediators (DBBM/BMP-2: 
13.35%±11.54%; DBBM/PDGF: 6.96%±9.73%) and only slightly increased in group DBBM 
(10.68%±13.78%) and the control group (4.95%±8.69%) compared to 8 weeks. No statistically 
significant differences were found at 16 weeks (p>0.05).  
The mean values for residual bone substitute material were similar in all groups at both 
time-points (p>0.05). A slight loss, however, was observed comparing the 8 to the 16-week 
time-point.  
The percentage of mineralized tissue (bone + bone substitute material) ranged between 
38.38%±13.98% for DBBM/BMP-2 and 1.25%±2.60% for control at 8 weeks. The control group 
demonstrated statistically significantly less mineralized tissue compared to the others groups 
(p=0.0009 vs. DBBM/BMP-2, p=0.0124 vs. DBBM/PDGF and p=0.0040 vs. DBBM group). At 16 
weeks the values ranged between 20.91%±15.70% for DBBM/BMP-2 and 4.95%±8.69% for 
control. 
The fBIC values on the buccal side were minimal for DBBM/BMP-2 (0.57mm±1.07mm) 
and maximal for control (3.72mm±2.09mm) at 8 weeks. The DBBM/BMP-2 group demonstrated 
a statistically significantly smaller fBIC value compared to the DBBM group (p=0.0015) and the 
control group (p=0.0087). At 16 weeks, no statistically significant differences were observed 
between the groups (p>0.05).  
Discussion 
The present experimental study demonstrated that the use of biological mediators 
significantly increased the regenerated area at 8 weeks compared to controls. At 16 weeks, 
however, the use of rhBMP-2 and rhPDGF-BB was not beneficial in terms of bone regeneration 
compared to the bone substitute material alone (DBBM).  
Descriptive histology revealed that the use of biological mediators (rhBMP-2; rhPDGF-
BB) affected the regeneration process in a positive way up to 8 weeks. RhBMP-2 has shown to 
be beneficial in terms of bone regeneration using a variety of bone substitute materials and for 
various indications (Thoma et al. 2010; Khojasteh et al. 2013; Khoshkam et al. 2015; Lee et al. 
2015). These findings are supported by a systematic review, showing the highest potential for 
new bone formation among other biological mediators, especially when rhBMP-2 was used in 
combination with an appropriate carrier material (Khojasteh et al. 2013). RhPDGF-BB was 
included in a recent systematic review with meta-analysis (Khoshkam et al. 2015). Based on 
five included studies evaluating the effects of rhPDGF significantly more bone formation was 
demonstrated compared to negative controls or carrier materials alone. This is supported by a 
further systematic review (Khojasteh et al. 2013) analyzing different types of biological 
mediators. In three of four studies, an advantage for rhPDGF-BB groups was observed 
compared to negative controls.  
From a clinical point of view, the aim would be to re-establish the ridge contour. For that 
purpose, the relative augmented area (RA/TDA) was calculated. The results of the present 
study indicated, at 8 weeks, a significantly better performance for the DBBM/BMP-2 group 
compared to DBBM and the control group. The weakest regeneration was obtained in the 
negative control group. Over time, between 8 and 16 weeks, a major proportion of the 
regenerated area in both groups using biological mediators was lost. Similar results with rhBMP-
2 were reported in previous studies in dogs showing enhanced bone formation compared to the 
control group at 8 weeks (Wikesjö et al. 2004) and at 12 weeks (Jovanovic et al. 2007), but no 
significant differences at 16 weeks (Smeets et al. 2009). A study using rhPDGF-BB in dogs, on 
standardized mandibular defects, reported similar results compared to a DBBM/PDGF group 
with a statistically significant higher mean augmented area compared to control sites at an early 
time-point (3 weeks) (Schwarz et al. 2009).  
The amount of regenerated bone and the extent of bone formation along the implant 
surface represent useful parameters to qualitatively assess the regenerated area. At 8 weeks, 
significantly more bone formation was observed for DBBM/BMP-2 compared to DBBM and the 
negative control group, but not compared to the DBBM/PDGF group. In line with a major loss of 
volume over time, both groups with biologic mediators revealed an extensive reduction in the 
amount of regenerated bone in order of 50.5% for the DBBM/BMP-2 group and 68.4% for the 
DBBM/PDGF group between 8 and 16 weeks. These outcomes are lined up with the reduction 
of mineralized tissue and bone substitute material. There was a decrease of mineralized tissue 
(45.5% for the DBBM/BMP-2, 56.8% for DBBM/PDGF and 3.2% for DBBM) and bone substitute 
material (33.7% for the DBBM/BMP-2, 35.9% for DBBM/PDGF and 43.2% for DBBM) in 
augmented groups between 8 and 16 weeks. This generalized loss could be due to the lack of a 
more stable and durable membrane. Previous study demonstrated that the carrier material plays 
a crucial role (Sigurdsson et al. 1996). In case non-space-maintaining collagen sponges are 
used, bone regeneration using rhBMP-2 is limited (Barboza et al. 2000).  
The fBICb showed more favorable results for the DBBM/BMP-2 group, with statistically 
significant differences compared to DBBM and control groups. No differences were found 
between the others groups. At 16 weeks the groups with biological mediators lost a 
considerable amount of bone, and the DBBM and control groups continued to improve the bone 
formation, resulting in no statistically significant differences. These outcomes corroborate with 
the relative augmented area (RA/TDA), regenerated bone and mineralized tissue results, where 
the new bone formation was faster on sites exposed to biological mediators, especially with 
rhBMP-2. At 16 weeks, no positive effect for the use of biologic mediators was observed. For 
DBBM/BMP-2, this could be explained by the short biological half-life, localized action and rapid 
local clearance (Kokubo et al. 2003). Clinically it is important to emphasize that the differences 
between DBBM/BMP-2 and the other groups were at least 1 mm for fBIC, or 20% of the total 
defect height. This difference, even though no statistically significantly different, might have a 
clinical relevance. The fBIC values for the DBBM/BMP-2 group were in line with previous 
publications (Yamashita et al. 2010; Thoma et al. 2010) using rhBMP-2 and smaller compared 
to control groups. 
The way rhBMP-2 and rhPDGF-BB interact with the surrounding tissues are 
substantially different. Both factors can act locally, but may also act systemically to affect the 
growth and function of distant cells and tissues. RhPDGF-BB is a so-callled proliferation factor 
mainly having a mitogenic function and thereby increasing the number of cells in the area. In 
contrast, rhBMP-2 is a differentiation and primarily responsible for the maturation of cells. The 
specific function of the two biologic mediators may at least in part explain the obtained data in 
the present study. At the earlier time-point, the overall response in terms of bone regeneration 
was stronger for rhBMP-2 compared to rhPDGF-BB and probably owing to a strong induction of 
osteoblast differentiation. RhPDGF-BB, however, did improve the outcomes in terms of bone 
regeneration compared to the bone substitute material alone, probably due to a its function of 
being mitogenic and enhancing angiogenesis.   
 
 
Conclusions 
Within the limitations of the present experimental study, the use of biologic mediators 
(rhBMP-2, rhPDGF-BB) can increase the amount of bone regeneration at dehiscence-type 
defects compared to controls at 8 weeks. The augmented area may undergo enhanced hard 
tissue remodeling processes during further healing preventing any clinical benefit for the use of 
biologic mediators compared to control groups at a later time-point.  
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Figure Legends 
Fig. 1. Clinical photographs of surgical procedures. Lateral view (a) and occlusal view (b) of 
box-type defects (mesio-distal width: 10 mm, height: 5 mm, depth: 5 mm) with dental implants 
placed flush with the lingual bone crest. Occlusal view (c) bone substitute material placed into 
defect (right side); empty control (left side). Lateral view (d) of pinned collagen membrane (left 
side) and bone substitute material placed into defect (right side). Lateral view (e) of pinned 
collagen membrane (left side) and control site with blood clot (right side).  
Fig. 2. Illustration of the region of interest (ROI; blue box) used for histomorphometric analysis 
(a). Illustration representing RA/TDA (light green area) (b). Illustration representing background 
(green), new bone formation (yellow), bone substitute material (blue) and connective tissue 
(dark red) (c).  
Fig. 3. Histologic slide at 25x magnification at 8 weeks. DBBM/BMP-2 group (a). DBBM/PDGF 
group (b). DBBM group (c). Control group (d). DBBM/BMP-2 = bovine-derived particulated bone 
mineral (DBBM) mixed with recombinant human bone morphogenetic protein-2 (rhBMP-2) and a 
collagen membrane (CM); DBBM/PDGF = DBBM mixed with recombinant platelet-derived 
growth factor (rhPDGF-BB) and CM; DBBM = DBBM and CM; control = empty control. B=native 
bone; NB=new bone formation; BS=bone substitute material. 
Fig. 4. Histologic slide at 25x magnification at 16 weeks. DBBM/BMP-2 group (a). DBBM/PDGF 
group (b). DBBM group (c). Control group (d). DBBM/BMP-2 = bovine-derived particulated bone 
mineral (DBBM) mixed with recombinant human bone morphogenetic protein-2 (rhBMP-2) and a 
collagen membrane (CM); DBBM/PDGF = DBBM mixed with recombinant platelet-derived 
growth factor (rhPDGF-BB) and CM; DBBM = DBBM and CM; control = empty control. B=native 
bone; NB=new bone formation; BS=bone substitute material. 
 
Table 
Table 1. Histomorphometrical analysis values at 8 weeks. 
 DBBM/BMP-2 DBBM/PDGF DBBM Control 
 Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) 
TDA (mm2) 7.56 (1.26) 7.34 (7.04; 8.00) 7.07 (1.09) 
7.50 
(6.21; 8.01) 5.89 (1.23) 
5.54 
(5.30; 5.75) 6.02 (1.81) 
4.73 
(4.70; 8.00) 
RA (mm2) 4.24 (1.20) 4.11 (3.12; 5.22) 3.57 (1.76) 
3.62 
(2.24; 5.12) 2.03 (1.17) 
1.60 
(1.20; 2.29) 0.07 (0.13) 
0.02 
(0.00; 0.05) 
RA/TDA (%) 56.95 (15.84)a 58.41
a 
(51.08; 71.06) 48.86 (19.81)
a 45.16
a 
(39.86; 63.90) 33.44 (14.09)
a 
30.18a 
(21.60; 
46.98) 
1.59 (2.84) 0.40 (0.00; 0.95) 
fBICl (mm) 0.04 (0.09 0.00 (0.00;0.00) 0.236 (0.36) 
0.00 
(0.00; 0.36) 0.12 (0.27) 
0.00 
(0.00; 0.00) 0.173 (0.26) 
0.00 
(0.00; 0.27) 
fBICb (mm) 0.57 (1.07)a, b 0.06
a, b 
(0.00; 0.33) 
1.84 
(1.96) 
1.92 
(0.00; 2.64) 3.65 (1.62) 
4.13 
(3.67; 4.74) 3.724 (2.09) 
4.68 
(4.39; 4.77) 
B (%) 26.97 (12.17)
a, 
b 
30.28a, b 
(28.76; 31.89) 
22.02 
(19.66) 
15.37 
(5.22; 39.72) 5.03 (4.30) 
2.57 
(2.46; 7.30) 1.25 (2.60) 
0.00 
(0.00; 0.37) 
BS (%) 11.41 (3.23) 9.48 (9.10; 13.67) 
12.18 
(5.83) 
9.64 
(9.57; 12.10) 14.53 (8.40) 
17.19 
(7.01; 19.43) 0.00 (0.00) 
0.00 
(0.00; 0.00) 
MT (%) 38.38 (13.98)a 41.00
a 
(39.10; 42.43) 34.20 (16.96)
a 27.47
a 
(27.40; 47.14) 19.56 (8.60)
a 
20.73a 
(11.96; 
26.84) 
1.25 (2.60) 0.00 (0.00; 0.37) 
ST (%) 56.81 (17.41) 58.47 (48.74; 60.60) 
58.32 
(18.41) 
67.46 
(47.41; 72.30) 77.04 (9.22) 
72.75 
(70.64; 85.43) 84.03 (12.54) 
86.00 
(74.66; 
91.79) 
a: significantly different with control group (p<0.01); b: significantly different with DBBM group (p<0.01).   
Table 2. Histomorphometrical analysis values at 16 weeks 
 DBBM/BMP-2 DBBM/PDGF DBBM Control 
 Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) Mean (SD) 
Median 
(Q1; Q3) 
TDA (mm2) 5.38 (1.42) 4.89  (4.80; 5.55) 5.64 (1.70) 
5.93 
(4.29; 6.25) 6.32 (1.57) 
5.68 
(5.13; 8.00) 6.47 (1.91) 
7.51 
(4.78; 8.00) 
RA (mm2) 1.29 (0.90) 1.72 (0.42; 1.84) 1.34 (1.45) 
0.71 
(0.20; 2.72) 1.98 (2.22) 
2.18 
(0.08; 2.19) 0.25 (0.42) 
0.06 
(0.04; 0.12) 
RA/TDA (%) 26.79 (19.83)  33.17 (8.69; 43.45) 23.78 (22.84) 
19.05 
(4.74; 45.75) 30.21 (29.14)  
38.38 
(1.67; 42.76) 5.07 (8.91)  
0.80 
(0.59; 2.92) 
fBICl (mm) 0.11 (0.13) 0.07 (0.00; 0.19) 0.23 (0.34) 
0.00 
(0.00; 0.41) 0.02 (0.05) 
0.00 
(0.00; 0.00) 0.51 (0.48) 
0.30 
(0.27; 0.78) 
fBICb (mm) 1.46 (1.28) 1.14 (0.80; 1.81) 3.22 (1.73) 
3.06 
(2.22; 4.46) 2.51 (1.55) 
2.91 
(1.04; 3.10) 3.40 (1.81) 
4.28 
(3.01; 4.31) 
B (%) 13.35 (11.54) 8.68 (6.44; 19.61) 6.96 (9.73) 
2.51 
(0.78; 8.13) 10.68 (13.78) 
9.72 
(0.00; 9.98) 4.95 (8.69) 
0.72 
(0.58 ;2.94) 
BS (%) 7.56 (6.38) 10.86 (0.91; 11.38) 7.81 (6.08) 
10.71 
(2.71; 11.67) 8.25 (8.65) 
4.70 
(1.58; 16.09) 0.00 (0.00) 
0.00 
(0.00; 0.00) 
MT (%) 20.91 (15.70) 20.59 (9.18; 30.99) 14.77 (13.91) 
14.19 
(3.49; 22.06) 18.93 (17.19) 
26.08 
(1.58; 28.59) 4.95 (8.69) 
0.72 
(0.58; 2.94) 
ST (%) 69.06 (22.71) 
78.83 
(61.11; 
84.92) 
73.59 (16.90) 77.94 (65.46; 78.06) 69.96 (15.93) 
65.81 
(62.78; 72.01) 68.45 (18.74) 
65.20 
(58.52; 
78.37) 
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